|
1
|
Fletcher CDM, Bridge JA, Hogendoorn PCW
and Mertens F: WHO classification of soft tissue tumours. 4th
edition. IARC; Lyon: 2013
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mack TM: Sarcomas and other malignancies
of soft tissue, retroperitoneum, peritoneum, pleura, heart,
mediastinum, and spleen. Cancer. 75 (Suppl 1):S211–S244. 1995.
View Article : Google Scholar
|
|
5
|
Dalal KM, Kattan MW, Antonescu CR, Brennan
MF and Singer S: Subtype specific prognostic nomogram for patients
with primary liposarcoma of the retroperitoneum, extremity, or
trunk. Ann Surg. 244:381–391. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu R, Rai A, Chen M, Suwakulsiri W,
Greening DW and Simpson RJ: Extracellular vesicles in
cancer-implications for future improvements in cancer care. Nat Rev
Clin Oncol. 15:617–638. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hoshino A, Costa-Silva B, Shen TL,
Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di
Giannatale A, Ceder S, et al: Tumour exosome integrins determine
organotropic metastasis. Nature. 527:329–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai H, Zhao H, Tang J and Wu H: Serum
miR-195 is a diagnostic and prognostic marker for osteosarcoma. J
Surg Res. 194:505–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hua J, Liu D, Cao L, Wang D, Wu T, Lin F,
Su P, Niu Y and Sun Y: Diagnostic and prognostic values of blood
microRNA-Let7A for osteosarcoma. J Bone Oncol. 12:65–68. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fei D, Li Y, Zhao D, Zhao K, Dai L and Gao
Z: Serum miR-9 as a prognostic biomarker in patients with
osteosarcoma. J Int Med Res. 42:932–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ouyang L, Liu P, Yang S, Ye S, Xu W and
Liu X: A three-plasma miRNA signature serves as novel biomarkers
for osteosarcoma. Med Oncol. 30:3402013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu JF, Wang YP, Zhang SJ, Chen Y, Gu HF,
Dou XF, Xia B, Bi Q and Fan SW: Exosomes containing differential
expression of microRNA and mRNA in osteosarcoma that can predict
response to chemotherapy. Oncotarget. 8:75968–75978. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vos M, Boeve WC, van Ginhoven TM, Sleijfer
S, Verhoef C and Grünhagen DJ: Impact of primary tumor location on
outcome of liposarcoma patients, a retrospective cohort study. Eur
J Surg Oncol. 45:2437–2442. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jour G, Gullet A, Liu M and Hoch BL:
Prognostic relevance of Fédération Nationale des Centres de Lutte
Contre le Cancer grade and MDM2 amplification levels in
dedifferentiated liposarcoma: A study of 50 cases. Mod Pathol.
28:37–47. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vincenzi B, Iuliani M, Zoccoli A, Pantano
F, Fioramonti M, De Lisi D, Frezza AM, Rabitti C, Perrone G, Onetti
Muda A, et al: Deregulation of dicer and mir-155 expression in
liposarcoma. Oncotarget. 6:10586–10591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kapodistrias N, Mavridis K, Batistatou A,
Gogou P, Karavasilis V, Sainis I, Briasoulis E and Scorilas A:
Assessing the clinical value of microRNAs in formalin-fixed
paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an
indicator of poor prognosis. Oncotarget. 8:6896–6913. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee DH, Amanat S, Goff C, Weiss LM, Said
JW, Doan NB, Sato-Otsubo A, Ogawa S, Forscher C and Koeffler HP:
Overexpression of miR-26a-2 in human liposarcoma is correlated with
poor patient survival. Oncogenesis. 2:e472013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Casadei L, Calore F, Creighton CJ,
Guescini M, Batte K, Iwenofu OH, Zewdu A, Braggio DA, Bill KL,
Fadda P, et al: Exosome-derived miR-25-3p and miR-92a-3p stimulate
liposarcoma progression. Cancer Res. 77:3846–3856. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Asano N, Matsuzaki J, Ichikawa M, Kawauchi
J, Takizawa S, Aoki Y, Sakamoto H, Yoshida A, Kobayashi E, Tanzawa
Y, et al: A serum microRNA classifier for the diagnosis of sarcomas
of various histological subtypes. Nat Commun. 10:12992019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Usuba W, Urabe F, Yamamoto Y, Matsuzaki J,
Sasaki H, Ichikawa M, Takizawa S, Aoki Y, Niida S, Kato K, et al:
Circulating miRNA panels for specific and early detection in
bladder cancer. Cancer Sci. 110:408–419. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka
Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda
T, et al: Integrated extracellular microRNA profiling for ovarian
cancer screening. Nat Commun. 9:43192018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa
M, Ikeda SI, Kato T, Kiyono T, Takeshita F, Kajiyama H, Kikkawa F
and Ochiya T: Malignant extracellular vesicles carrying MMP1 mRNA
facilitate peritoneal dissemination in ovarian cancer. Nat Commun.
8:144702017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshioka Y, Konishi Y, Kosaka N, Katsuda
T, Kato T and Ochiya T: Comparative marker analysis of
extracellular vesicles in different human cancer types. J Extracell
Vesicles. 18:22013.PubMed/NCBI
|
|
27
|
Zhou Y, Yamamoto Y, Takeshita F, Yamamoto
T, Xiao Z and Ochiya T: Delivery of miR-424-5p via extracellular
vesicles promotes the apoptosis of MDA-MB-231 TNBC cells in the
tumor microenvironment. Int J Mol Sci. 22:8442021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iwamoto Y, Tanaka K, Isu K, Kawai A,
Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, et al:
Multiinstitutional phase II study of neoadjuvant chemotherapy for
osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop
Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bacci G, Bertoni F, Longhi A, Ferrari S,
Forni C, Biagini R, Bacchini P, Donati D, Manfrini M, Bernini G and
Lari S: Neoadjuvant chemotherapy for high-grade central
osteosarcoma of the extremity. Histologic response to preoperative
chemotherapy correlates with histologic subtype of the tumor.
Cancer. 97:3068–3075. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bacci G, Briccoli A, Ferrari S, Longhi A,
Mercuri M, Capanna R, Donati D, Lari S, Forni C and DePaolis M:
Neoadjuvant chemotherapy for osteosarcoma of the extremity:
Long-term results of the Rizzoli's 4th protocol. Eur J Cancer.
37:2030–2039. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bajpai J, Chandrasekharan A, Talreja V,
Simha V, Chandrakanth MV, Rekhi B, Khurana S, Khan A, Vora T, Ghosh
J, et al: Outcomes in non-metastatic treatment naive extremity
osteosarcoma patients treated with a novel non-high
dosemethotrexate-based, dose-dense combination chemotherapy regimen
‘OGS-12’. Eur J Cancer. 85:49–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: Where do we go from here? Paediatr Drugs.
10:315–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Henricks WH, Chu YC, Goldblum JR and Weiss
SW: Dedifferentiated liposarcoma: A clinicopathological analysis of
155 cases with a proposal for an expanded definition of
dedifferentiation. Am J Surg Pathol. 21:271–281. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lian F, Cui Y, Zhou C, Gao K and Wu L:
Identification of a plasma four-microRNA panel as potential
noninvasive biomarker for osteosarcoma. PLoS One. 10:e01214992015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fujiwara T, Uotani K, Yoshida A, Morita T,
Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, et al:
Clinical significance of circulating miR-25-3p as a novel
diagnostic and prognostic biomarker in osteosarcoma. Oncotarget.
8:33375–33392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Boro A, Bauer D, Born W and Fuchs B:
Plasma levels of miRNA-155 as a powerful diagnostic marker for
dedifferentiated liposarcoma. Am J Cancer Res. 6:544–552.
2016.PubMed/NCBI
|
|
37
|
Feng F, Zhu X, Wang C, Chen L, Cao W, Liu
Y, Chen Q and Xu W: Downregulation of hypermethylated in cancer-1
by miR-4532 promotes adriamycin resistance in breast cancer cells.
Cancer Cell Int. 18:1272018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kanlikilicer P, Rashed MH, Bayraktar R,
Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM,
Rodriguez-Aguayo C, et al: Ubiquitous release of exosomal tumor
suppressor miR-6126 from ovarian cancer cells. Cancer Res.
76:7194–7207. 2016. View Article : Google Scholar : PubMed/NCBI
|
